- Home
- AMRC vs JANX Comparison
AMRC vs JANX Comparison
Compare AMRC & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRC
- JANX
- Stock Information
- Founded
- AMRC 2000
- JANX 2017
- Country
- AMRC United States
- JANX United States
- Employees
- AMRC N/A
- JANX N/A
- Industry
- AMRC Engineering & Construction
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- AMRC Consumer Discretionary
- JANX Health Care
- Exchange
- AMRC Nasdaq
- JANX Nasdaq
- Market Cap
- AMRC 1.3B
- JANX 1.4B
- IPO Year
- AMRC 2010
- JANX 2021
- Fundamental
- Price
- AMRC $27.10
- JANX $24.57
- Analyst Decision
- AMRC Buy
- JANX Strong Buy
- Analyst Count
- AMRC 8
- JANX 10
- Target Price
- AMRC $23.00
- JANX $79.50
- AVG Volume (30 Days)
- AMRC 617.6K
- JANX 645.3K
- Earning Date
- AMRC 11-06-2025
- JANX 11-05-2025
- Dividend Yield
- AMRC N/A
- JANX N/A
- EPS Growth
- AMRC 9.21
- JANX N/A
- EPS
- AMRC 1.17
- JANX N/A
- Revenue
- AMRC $1,858,653,000.00
- JANX $439,000.00
- Revenue This Year
- AMRC $9.95
- JANX N/A
- Revenue Next Year
- AMRC $9.35
- JANX $591.60
- P/E Ratio
- AMRC $23.34
- JANX N/A
- Revenue Growth
- AMRC 22.85
- JANX N/A
- 52 Week Low
- AMRC $8.49
- JANX $21.97
- 52 Week High
- AMRC $39.68
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- AMRC 65.55
- JANX 52.74
- Support Level
- AMRC $23.77
- JANX $23.62
- Resistance Level
- AMRC $28.63
- JANX $25.35
- Average True Range (ATR)
- AMRC 1.45
- JANX 1.13
- MACD
- AMRC 0.04
- JANX 0.18
- Stochastic Oscillator
- AMRC 68.52
- JANX 67.92
About AMRC Ameresco Inc.
Ameresco Inc provides energy efficiency solutions for facilities in North America and Europe. It focuses on projects that reduce energy, also focuses on the operations and maintenance costs of governmental, educational, utility, healthcare, and other institutional, commercial, and industrial entities facilities. Ameresco distributes solar energy products and systems, such as PV panels, solar regulators, solar charge controllers, inverters, solar-powered lighting systems, solar-powered water pumps, solar panel mounting hardware, and other system components. The company's segment includes U.S. Regions; U.S. Federal; Canada; Alternative Fuels; Non-Solar DG and All Other. It derives a majority of its revenue from the U.S. Regions segment.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.